Development of a high yield expression and purification system for Domain I of Beta-2-glycoprotein I for the treatment of APS

BMC Biotechnology

Volumn 15, Issue 1, 2015, Pages

  McDonnell, Thomas ^a   Pericleous, Charis ^a   Laurine, Emmanuelle ^b   Tommasi, Rita ^b   Garza Garcia, Acely ^c   Giles, Ian ^a   Ioannou, Yiannis ^a   Rahman, Anisur ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Antitope Ltd   (United Kingdom)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

Antiphospholipid syndrome; Automated; Beta 2 Glycoprotein I; Domain I; E. Coli; Inclusion bodies; Protein production

Indexed keywords

ESCHERICHIA COLI; PROTEINS;

ANTIPHOSPHOLIPID SYNDROMES; AUTOMATED; E. COLI; INCLUSION BODIES; PROTEIN PRODUCTION;

GLYCOPROTEINS;

BETA2 GLYCOPROTEIN 1; HYBRID PROTEIN;

ADULT; AMINO TERMINAL SEQUENCE; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SYNTHESIS; ESCHERICHIA COLI; FEMALE; HUMAN; IN VITRO STUDY; INFORMED CONSENT; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PURIFICATION; CELL INCLUSION; GENETICS; ISOLATION AND PURIFICATION; LABORATORY AUTOMATION; METABOLISM; MIDDLE AGED; PROTEIN TERTIARY STRUCTURE;

ADULT; ANTIPHOSPHOLIPID SYNDROME; AUTOMATION, LABORATORY; BETA 2-GLYCOPROTEIN I; ESCHERICHIA COLI; FEMALE; HUMANS; INCLUSION BODIES; MALE; MIDDLE AGED; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS;

EID: 84947434780     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/s12896-015-0222-0     Document Type: Article

References (39)

1. Kelly SJ, Delnomdedieu M, Oliverio MI, Williams LD, Saifer MG, Sherman MR, et al. Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly (ethylene glycol)-modified uricase. J Am Soc Nephrol. 2001;12(5):1001-9.
2. Sundy JS, Becker MA, Baraf HS, Barkhuizen A, Moreland LW, Huang W, et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum. 2008;58(9):2882-91.
3. Sundy JS, Ganson NJ, Kelly SJ, Scarlett EL, Rehrig CD, Huang W, et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum. 2007;56(3):1021-8.
4. Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly (ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther. 2006;8(1):R12.
5. Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306(7):711-20.
6. Sherman MR, Saifer MG, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev. 2008;60(1):59-68.
7. Lipton JH, Khoroshko N, Golenkov A, Abdulkadyrov K, Nair K, Raghunadharao D, et al. Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naive, chronic-phase chronic myelogenous leukemia. Leuk Lymphoma. 2007;48(3):497-505.
8. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales Jr FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975-82.
9. Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis. 2009;68(6):805-11.
10. Horton S, Walsh C, Emery P. Certolizumab pegol for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2012;12(2):235-49.
11. Keystone E, Heijde D, Mason Jr D, Landewe R, Vollenhoven RV, Combe B, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2008;58(11):3319-29.
12. Voulgaridou GP, Mantso T, Chlichlia K, Panayiotidis MI, Pappa A. Efficient E. coli expression strategies for production of soluble human crystallin ALDH3A1. PLoS One. 2013;8(2):e56582.
13. Johnson IS. Human insulin from recombinant DNA technology. Science. 1983;219(4585):632-7.
14. Chevaliez S, Pawlotsky JM. Interferon-based therapy of hepatitis C. Adv Drug Deliv Rev. 2007;59(12):1222-41.
15. Scopes RK. Protein purification: principles and practice. 2nd ed. New York: Springer; 1987.
16. Smales CM, James DC. Therapeutic proteins: methods and protocols. Totowa, N.J.: Humana Press; 2005.
17. Lobstein J, Emrich CA, Jeans C, Faulkner M, Riggs P, Berkmen M. SHuffle, a novel Escherichia coli protein expression strain capable of correctly folding disulfide bonded proteins in its cytoplasm. Microb Cell Factories. 2012;11.
18. Bessette PH, Aslund F, Beckwith J, Georgiou G. Efficient folding of proteins with multiple disulfide bonds in the Escherichia coli cytoplasm. Proc Natl Acad Sci U S A. 1999;96(24):13703-8.
19. Jaffe SR, Strutton B, Levarski Z, Pandhal J, Wright PC. Escherichia coli as a glycoprotein production host: recent developments and challenges. Curr Opin Biotechnol. 2014;30:205-10.
20. De Jesus M, Wurm FM. Manufacturing recombinant proteins in kg-ton quantities using animal cells in bioreactors. Eur J Pharm Biopharm. 2011;78(2):184-8.
21. Wurm FM. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol. 2004;22(11):1393-8.
22. Macauley-Patrick S, Fazenda ML, McNeil B, Harvey LM. Heterologous protein production using the Pichia pastoris expression system. Yeast. 2005;22(4):249-70.
23. Ioannou Y, Romay-Penabad Z, Pericleous C, Giles I, Papalardo E, Vargas G, et al. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept. J Thromb Haemost. 2009;7(5):833-42.
24. Lambrianides A, Carroll CJ, Pierangeli SS, Pericleous C, Branch W, Rice J, et al. Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. J Immunol. 2010;184(12):6622-8.
25. Ioannou Y, Pericleous C, Giles I, Latchman DS, Isenberg DA, Rahman A. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta (2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum. 2007;56(1):280-90.
26. Alessandri C, Conti F, Pendolino M, Mancini R, Valesini G. New autoantigens in the antiphospholipid syndrome. Autoimmun Rev. 2011;10(10):609-16.
27. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 1990;335(8705):1544-7.
28. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990;87(11):4120-4.
29. Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A. 1998;95(26):15542-6.
30. Pierangeli SS, Espinola RG, Liu X, Harris EN. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res. 2001;88(2):245-50.
31. Pierangeli SS, Liu SW, Anderson G, Barker JH, Harris EN. Thrombogenic properties of murine anti-cardiolipin antibodies induced by beta 2 glycoprotein 1 and human immunoglobulin G antiphospholipid antibodies. Circulation. 1996;94(7):1746-51.
32. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995;332(15):993-7.
33. Reddel SW, Wang YX, Sheng YH, Krilis SA. Epitope studies with anti-beta 2-glycoprotein I antibodies from autoantibody and immunized sources. J Autoimmun. 2000;15(2):91-6.
34. Ioannou Y, Rahman A. Domain I of beta2-glycoprotein I: its role as an epitope and the potential to be developed as a specific target for the treatment of the antiphospholipid syndrome. Lupus. 2010;19(4):400-5.
35. Bertolaccini ML, Amengual O, Andreoli L, Atsumi T, Chighizola CB, Forastiero R, et al. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev. 2014;13(9):917-30.
36. Ioannou Y, Giles I, Lambrianides A, Richardson C, Pearl LH, Latchman DS, et al. A novel expression system of domain I of human beta2 glycoprotein I in Escherichia coli. BMC Biotechnol. 2006;6:8.
37. Pericleous C, Miles J, Esposito D, Garza-Garcia A, Driscoll PC, Lambrianides A, et al. Evaluating the conformation of recombinant domain I of beta (2)-glycoprotein I and its interaction with human monoclonal antibodies. Mol Immunol. 2011;49(1-2):56-63.
38. Fink AL. Protein aggregation: folding aggregates, inclusion bodies and amyloid. Fold Des. 1998;3(1):R9-23.
39. Studier FW. Protein production by auto-induction in high density shaking cultures. Protein Expr Purif. 2005;41(1):207-34.